In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease.doi:10.1023/B:UROL.0000020306.08275.49R. NishioY. FuruyaO. NagakawaH. FuseInternational Urology & NephrologyNishio R,Furuya Y,Nagakawa O. Metastatic prostate cancer with normal level of ...
The clinical and pathological features of metastatic prostate cancer with normal level of serum prostate-specific antigen (PSA) were investigated. Four patients with metastatic prostate cancer had serum PSA within the normal range at the diagnosis. All tumors were poorly-differentiated adenocarcinoma. End...
PATIENTS & METHODS: Parallel determination of serumprostatic specific antigen (PSA) and serum prostatic acid phosphatase (PAP) was done in forty-eight patientswith metastatic prostate cancer. Patients with normal PSA and raised PAP were placed in Group-I andpatients with normal PAP but raised PSA ...
Our patient had only received 7 days of aspirin before his serum PSA was found to have normalised, and is therefore of questionable relevance. Complete remissions to hormonal manipulation have been described in patients with prostate cancer [12, 13], but this seems an unlikely mechanism in this...
Although treatment options for men with metastatic castrate-resistant prostate cancer have improved in recent years, the outlook for patients remains poor, with overall survival in the region of 2 years. Response rates with chemotherapy are modest a
Metastatic prostate cancer with normal level of serum prostate-specific antigen. The clinical and pathological features of metastatic prostate cancer with normal level of serum prostate-specific antigen (PSA) were investigated. Four pat... R Nishio,Y Furuya,O Nagakawa,... - 《International Urology ...
These analyses showed that marker expression for both cell lines was consistent with epithelial prostate cancer provenance (positive for CK 8/18, PSA, AR, MUC-1, and co-expression of Vimentin, as well as undetectable expression of vWF [endothelial lineage] and CD45 [haematopoietic lineage]). ...
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...
As a member of the nuclear receptor superfamily of ligand-activated transcription factors, AR is a key regulator of normal prostate function as well as cancer development. For decades we have known that PCa cell proliferation is inhibited when low serum levels of testosterone and dihydrotestosterone ...
The trends are startlingly different. The incidence of metastatic prostate cancer fell by approximately 50% within 7 years of the start of widespread PSA use in 1990; however, rates of metastatic breast cancer remained remarkably stable following the initiation of widespread mammography screening in ...